Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Extension Study of ATN-103 in Rheumatoid Arthritis
2009-015636-15Phase 2Completed
- Sponsor
- Pfizer
- Start
- Feb 2010
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ozoralizumab in rheumatoid arthritis (RA), sponsored by Pfizer. Primary endpoint: Long-term safety and tolerability of ATN-103. Started Feb 2010; status: completed.
02
Drugs
ozoralizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2009-015636-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015636-15.